Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
ALECENSA® (alectinib) United Kingdom
Avastin® (bevacizumab) United Kingdom
Evrysdi®▼ (risdiplam) United Kingdom
GAZYVARO® (obinutuzumab) United Kingdom
HEMLIBRA® (emicizumab) United Kingdom
Herceptin® (trastuzumab) IV 150 mg United Kingdom
Herceptin® (trastuzumab) SC 600 mg United Kingdom
Kadcyla® (trastuzumab emtansine) United Kingdom
Lunsumio®▼ (mosunetuzumab) United Kingdom
OCREVUS® IV (ocrelizumab) United Kingdom
OCREVUS® SC (ocrelizumab) United Kingdom
Perjeta® (pertuzumab) United Kingdom
PHESGO®▼ (pertuzumab-trastuzumab) United Kingdom
Polivy®▼ (polatuzumab vedotin) United Kingdom
Rozlytrek®▼ (entrectinib) United Kingdom
TECENTRIQ® (atezolizumab) United Kingdom
Vabysmo®▼ (faricimab) United Kingdom
Rozlytrek is subject to a conditional marketing authorisation.
Medicinal products that display the black triangle symbol ▼ are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 36 7554. For medicines which are biological, healthcare professionals should report adverse reactions by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.